MoonLake Immunotherapeutics MLTX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -60.5%-35.3pp | -25.2%-12.0pp | -13.2%— | —— | |
| Return on invested capital | -155.5%-65.3pp | -90.2%+96.9pp | -187%— | —— | |
| Liquidity | |||||
| Current ratio | 9.3×-11.8× | 21.1×-30.5× | 51.6×+41.6× | 10×+9.5× | |
| Leverage | |||||
| Debt-to-equity | 0.2×+0.2× | 0×0.0× | 0×0.0× | 0×— | |
| Per Share | |||||
| Book value per share | $4.72-33.5% | $7.11-29.6% | $10.09+506% | $1.67+212% | |
| Valuation | |||||
| Market capitalization | $933.77M-72.7% | $3.41B-5.6% | $3.62B+787% | $407.86M+11.7% | |
| Price / book | 3.1×-4.6× | 7.6×+0.3× | 7.3×-1.0× | 8.3×— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do MoonLake Immunotherapeutics's ratios come from?
- Every ratio is computed from MoonLake Immunotherapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.